Business Description
Chimerix Inc
NAICS : 325412
SIC : 2834
ISIN : US16934W1062
Description
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 211.54 | |||||
| Equity-to-Asset | 0.86 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -0.56 | |||||
| Beneish M-Score | 86.74 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -64 | |||||
| 3-Year EBITDA Growth Rate | -13.9 | |||||
| 3-Year EPS without NRI Growth Rate | -9.9 | |||||
| 3-Year FCF Growth Rate | -10.4 | |||||
| 3-Year Book Growth Rate | 23 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 7.69 | |||||
| Future 3-5Y Total Revenue Growth Rate | 474.81 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 76.54 | |||||
| 9-Day RSI | 77.34 | |||||
| 14-Day RSI | 77.39 | |||||
| 6-1 Month Momentum % | -1.91 | |||||
| 12-1 Month Momentum % | 1.13 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.33 | |||||
| Quick Ratio | 6.33 | |||||
| Cash Ratio | 6.12 | |||||
| Days Sales Outstanding | 137.74 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -12.3 | |||||
| Shareholder Yield % | 0.26 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -58380.5 | |||||
| Net Margin % | -52574.84 | |||||
| FCF Margin % | -43887.07 | |||||
| ROE % | -48.22 | |||||
| ROA % | -43.12 | |||||
| ROIC % | -325.54 | |||||
| ROC (Joel Greenblatt) % | -5768.39 | |||||
| ROCE % | -53.22 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 3340 | |||||
| PB Ratio | 2.21 | |||||
| Price-to-Tangible-Book | 2.21 | |||||
| EV-to-EBIT | -1.47 | |||||
| EV-to-EBITDA | -1.47 | |||||
| EV-to-Revenue | 855.48 | |||||
| EV-to-Forward-Revenue | 21.57 | |||||
| EV-to-FCF | -1.93 | |||||
| Price-to-Median-PS-Value | 67 | |||||
| Price-to-Net-Current-Asset-Value | 2.55 | |||||
| Price-to-Net-Cash | 2.65 | |||||
| Earnings Yield (Greenblatt) % | -68.03 | |||||
| FCF Yield % | -23.44 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Chimerix Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.147 | ||
| EPS (TTM) (€) | -0.871 | ||
| Beta | 0.14 | ||
| Volatility % | 41.03 | ||
| 14-Day RSI | 77.39 | ||
| 14-Day ATR (€) | 0.132128 | ||
| 20-Day SMA (€) | 1.9798 | ||
| 12-1 Month Momentum % | 1.13 | ||
| 52-Week Range (€) | 0.687 - 3.02 | ||
| Shares Outstanding (Mil) | 89.94 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Chimerix Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Chimerix Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Chimerix Inc Frequently Asked Questions
What is Chimerix Inc(STU:CXF)'s stock price today?
The current price of STU:CXF is €2.68. The 52 week high of STU:CXF is €3.02 and 52 week low is €0.69.
When is next earnings date of Chimerix Inc(STU:CXF)?
The next earnings date of Chimerix Inc(STU:CXF) is 2025-02-28 Est..
Does Chimerix Inc(STU:CXF) pay dividends? If so, how much?
Chimerix Inc(STU:CXF) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers